+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Absorption and Action of Insulin Added to Peritoneal Dialysate in Dogs

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The transperitoneal kinetics of insulin transfer during peritoneal dialysis and its biologic effects were evaluated in dogs. Changes in plasma glucose and immunoreactive insulin (iRI) during dialysis with 10, 30, and 120 U insulin/ liter of dialysate and during intravenous infusions of insulin at 0.5 or 1.5 U/h, and the recovery of <sup>125</sup>I-insulin added to dialysate were measured. As insulin was increased via the intravenous or the intraperitoneal route, there was a greater fall in plasma glucose and a greater rise in plasma iRI. With intravenous insulin, plasma iRI rose and plateaued within 30 min, with a relatively predictable fall in plasma glucose. With intraperitoneal insulin, plasma iRI rose more slowly, plateaued at 3 h with 10 and 30 insulin/liter dialysate but continued to rise over 5 h with 120 U insulin/liter dialysate. From the observed relationship between dose of intravenous insulin and fall in plasma glucose, the quantities of intraperitoneal insulin absorbed and active were estimated. The percentages of intraperitoneal insulin absorbed, derived from fall in plasma glucose and from loss of <sup>125</sup>I-insulin in dialysate, were 6.1 and 25 ± 5%, respectively. The greater loss of intraperitoneal <sup>125</sup>I-insulin may be explained by its mesenteric binding; subsequent release could account for the slow rise of iRI. Intraperitoneal insulin has been proposed for management of hyperglycemia during peritoneal dialysis of diabetic patients. Present results suggest that intraperitoneal insulin should be used cautiously and in low concentrations because of possible cumulative effects.

          Related collections

          Author and article information

          S. Karger AG
          02 December 2008
          : 23
          : 4
          : 174-180
          Medical and Research Services, Veterans Administration Wadsworth Hospital Center and Department of Medicine, UCLA School of Medicine, Los Angeles, Calif.
          181630 Nephron 1979;23:174–180
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article